Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
runxinbio.com is the corporate website of Suzhou Runxin Biotechnology Co., Ltd. According to the site, the company is based in Suzhou BioBAY and was founded by a returnee technical team with biopharmaceutical experience. It positions itself as a high-tech company specializing in innovative drug R&D, with a focus on small-molecule oncology drugs.
The website mainly serves three purposes: corporate presentation, pipeline disclosure, and recruitment. The R&D section lists investigational products such as RX108, RX208, RX518 (CK-101), and RX608, and highlights a self-developed targeted drug discovery platform. Company news discloses milestones including first-patient dosing in China Phase I trials for RX108-A tablets and RX608, Breakthrough Therapy Designation for RX208, and first-patient dosing in a registrational Phase III trial for RX518. These updates allow external partners to make an initial assessment of the company’s pipeline activity. The recruitment section covers roles such as Chief Medical Officer, Clinical Medical Director, Clinical Project Manager, pharmaceutical formulation, and pharmacology/toxicology positions, suggesting strong needs in clinical development and regulatory advancement.
This is not an online transaction platform for consumers or business customers, and it does not provide drug prices, R&D service fees, or licensing/partnership quotations. Its commercialization information is mainly reflected in pipeline progress and partnership news, such as the exclusive licensing collaboration with Henlius for the BRAF V600E inhibitor RX208.
The strengths are its focused positioning around innovative oncology drugs, as well as disclosure of clinical trial information across China, the United States, Australia, and other regions, indicating a degree of international development perspective. The website also provides Chinese and English entry points, making it easier for overseas institutions to understand the company.
The limitations lie in the relatively shallow depth of information. The technology platform is described only in conceptual terms, and the product pages lack a complete tabular pipeline with indications, targets, clinical stages, and registration numbers. The corporate culture page is rather thin, and there is no clear systematic information on patents, publications, investor relations, or BD partnership processes.
The site is suitable for pharmaceutical BD teams, clinical research organizations, CRO/SMO providers, healthcare investors, oncology drug researchers, and job seekers with clinical development experience. For ordinary patients who want to learn about participation in clinical trials, the information currently available on the official website is not sufficient; they would still need to confirm details through hospitals, clinical trial registries, or official contact channels.
Both the domain and the company entity are based in China, and the website is primarily in Chinese. Under normal circumstances, it should be directly accessible from mainland China.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on runxinbio.com official site.
runxinbio.com is an China Health provider. TG4G tracks its product information, an overall rating of 4.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach runxinbio.com directly.